 Mark Gerich
Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 9 | 2022 | 196 | 2.010 |
Why?
| | Medical Marijuana | 4 | 2017 | 101 | 1.490 |
Why?
| | Inflammatory Bowel Diseases | 9 | 2022 | 290 | 1.400 |
Why?
| | Immunosuppressive Agents | 5 | 2020 | 683 | 1.400 |
Why?
| | Gastrointestinal Diseases | 3 | 2016 | 186 | 1.370 |
Why?
| | Thalidomide | 2 | 2015 | 25 | 1.020 |
Why?
| | Colitis, Ulcerative | 5 | 2020 | 105 | 0.960 |
Why?
| | Colitis | 8 | 2020 | 219 | 0.870 |
Why?
| | Intestinal Mucosa | 7 | 2021 | 527 | 0.690 |
Why?
| | Drug Resistance | 1 | 2013 | 166 | 0.430 |
Why?
| | Salvage Therapy | 1 | 2013 | 129 | 0.420 |
Why?
| | Tacrolimus | 1 | 2013 | 149 | 0.420 |
Why?
| | Intestines | 3 | 2021 | 330 | 0.410 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 19 | 0.400 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.400 |
Why?
| | Intestinal Neoplasms | 1 | 2011 | 23 | 0.390 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1159 | 0.380 |
Why?
| | Antiporters | 2 | 2021 | 16 | 0.380 |
Why?
| | Mercaptopurine | 1 | 2010 | 15 | 0.370 |
Why?
| | Spondylitis, Ankylosing | 2 | 2021 | 42 | 0.370 |
Why?
| | Precision Medicine | 1 | 2013 | 354 | 0.360 |
Why?
| | Allopurinol | 1 | 2010 | 82 | 0.360 |
Why?
| | Gastrointestinal Microbiome | 3 | 2022 | 538 | 0.350 |
Why?
| | Acidosis | 2 | 2021 | 84 | 0.350 |
Why?
| | Spondylarthritis | 2 | 2021 | 35 | 0.350 |
Why?
| | Enzyme Inhibitors | 2 | 2010 | 812 | 0.340 |
Why?
| | Algorithms | 3 | 2020 | 1520 | 0.330 |
Why?
| | Colon | 2 | 2020 | 237 | 0.320 |
Why?
| | Tryptophan | 2 | 2021 | 138 | 0.320 |
Why?
| | Ileitis | 2 | 2021 | 25 | 0.310 |
Why?
| | Patient Acceptance of Health Care | 3 | 2022 | 683 | 0.300 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1273 | 0.280 |
Why?
| | Dextran Sulfate | 5 | 2020 | 71 | 0.270 |
Why?
| | Endocannabinoids | 2 | 2017 | 37 | 0.270 |
Why?
| | Adenocarcinoma | 1 | 2011 | 806 | 0.250 |
Why?
| | Legislation, Drug | 2 | 2016 | 78 | 0.250 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 174 | 0.240 |
Why?
| | Humans | 33 | 2023 | 118053 | 0.230 |
Why?
| | Microbiota | 2 | 2022 | 656 | 0.220 |
Why?
| | Metabolomics | 3 | 2022 | 540 | 0.200 |
Why?
| | Infliximab | 3 | 2020 | 94 | 0.200 |
Why?
| | Ustekinumab | 1 | 2020 | 13 | 0.190 |
Why?
| | Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 4 | 0.190 |
Why?
| | Mucin 5AC | 1 | 2020 | 46 | 0.190 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 379 | 0.180 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 144 | 0.180 |
Why?
| | Inflammation | 4 | 2019 | 2545 | 0.180 |
Why?
| | Metagenomics | 1 | 2021 | 134 | 0.180 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 58 | 0.180 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 192 | 0.170 |
Why?
| | Quality Assurance, Health Care | 1 | 2021 | 323 | 0.170 |
Why?
| | Membrane Transport Proteins | 1 | 2020 | 136 | 0.170 |
Why?
| | Receptors, Cannabinoid | 2 | 2017 | 13 | 0.160 |
Why?
| | Intraepithelial Lymphocytes | 1 | 2018 | 12 | 0.160 |
Why?
| | Receptors, Interleukin-10 | 1 | 2018 | 5 | 0.160 |
Why?
| | Health Care Costs | 1 | 2021 | 390 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 694 | 0.160 |
Why?
| | Thrombophilia | 1 | 2018 | 62 | 0.160 |
Why?
| | Ambulatory Care | 1 | 2021 | 481 | 0.160 |
Why?
| | Microfluidic Analytical Techniques | 1 | 2018 | 75 | 0.150 |
Why?
| | Middle Aged | 9 | 2021 | 27431 | 0.150 |
Why?
| | Adult | 11 | 2021 | 31227 | 0.150 |
Why?
| | Thrombelastography | 1 | 2018 | 142 | 0.150 |
Why?
| | Interleukin-10 Receptor alpha Subunit | 1 | 2017 | 6 | 0.150 |
Why?
| | Neutrophils | 2 | 2019 | 1136 | 0.150 |
Why?
| | Male | 13 | 2021 | 57370 | 0.150 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 44 | 0.150 |
Why?
| | Quality of Health Care | 1 | 2021 | 586 | 0.140 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2016 | 13 | 0.140 |
Why?
| | Cannabinoids | 2 | 2017 | 115 | 0.140 |
Why?
| | Nerve Tissue Proteins | 1 | 2020 | 547 | 0.140 |
Why?
| | Myeloid Cells | 1 | 2017 | 127 | 0.140 |
Why?
| | Hospitalization | 2 | 2022 | 1778 | 0.140 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2017 | 149 | 0.140 |
Why?
| | Clostridium Infections | 1 | 2016 | 57 | 0.140 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 28 | 0.140 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 668 | 0.130 |
Why?
| | Inflammasomes | 1 | 2017 | 120 | 0.130 |
Why?
| | Indoles | 1 | 2018 | 310 | 0.130 |
Why?
| | Delivery of Health Care | 1 | 2021 | 861 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2022 | 12921 | 0.120 |
Why?
| | Nausea | 1 | 2014 | 106 | 0.120 |
Why?
| | Disease Models, Animal | 6 | 2021 | 3670 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2021 | 3142 | 0.120 |
Why?
| | Vomiting | 1 | 2014 | 123 | 0.120 |
Why?
| | Steroids | 1 | 2014 | 154 | 0.120 |
Why?
| | United States | 4 | 2021 | 12477 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 467 | 0.110 |
Why?
| | Mice | 9 | 2021 | 15424 | 0.110 |
Why?
| | Female | 9 | 2021 | 61140 | 0.110 |
Why?
| | Attitude to Health | 1 | 2016 | 410 | 0.110 |
Why?
| | alpha 1-Antitrypsin | 1 | 2013 | 111 | 0.100 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 13 | 0.100 |
Why?
| | Administration, Oral | 1 | 2013 | 751 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 632 | 0.090 |
Why?
| | Guanine Nucleotides | 1 | 2010 | 16 | 0.090 |
Why?
| | Thionucleotides | 1 | 2010 | 34 | 0.090 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 302 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 1928 | 0.090 |
Why?
| | Methyltransferases | 1 | 2010 | 61 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4571 | 0.090 |
Why?
| | Chronic Disease | 3 | 2022 | 1634 | 0.090 |
Why?
| | Animals | 10 | 2021 | 33101 | 0.080 |
Why?
| | Prospective Studies | 3 | 2022 | 6443 | 0.080 |
Why?
| | Genotype | 1 | 2013 | 1859 | 0.080 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2008 | 20 | 0.080 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 732 | 0.080 |
Why?
| | Prognosis | 2 | 2013 | 3420 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2020 | 2664 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2008 | 64 | 0.080 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 551 | 0.080 |
Why?
| | Disease Susceptibility | 2 | 2021 | 330 | 0.070 |
Why?
| | Young Adult | 2 | 2013 | 10705 | 0.070 |
Why?
| | Homeostasis | 2 | 2020 | 589 | 0.070 |
Why?
| | Immunity, Innate | 1 | 2011 | 743 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2013 | 2238 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 4885 | 0.060 |
Why?
| | Prevalence | 1 | 2010 | 2321 | 0.060 |
Why?
| | Cell Line | 2 | 2020 | 2688 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2023 | 152 | 0.060 |
Why?
| | Receptors, KIR | 1 | 2023 | 89 | 0.050 |
Why?
| | Phosphorylation | 2 | 2021 | 1617 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 298 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 2916 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 311 | 0.050 |
Why?
| | Nuclear Receptor Subfamily 4, Group A, Member 1 | 1 | 2021 | 12 | 0.050 |
Why?
| | Cost Savings | 1 | 2021 | 77 | 0.050 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2021 | 29 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 564 | 0.050 |
Why?
| | Granzymes | 1 | 2021 | 40 | 0.050 |
Why?
| | Ileum | 1 | 2021 | 100 | 0.050 |
Why?
| | Organoids | 1 | 2021 | 75 | 0.050 |
Why?
| | Adalimumab | 1 | 2020 | 43 | 0.050 |
Why?
| | Azathioprine | 1 | 2020 | 51 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2021 | 193 | 0.050 |
Why?
| | Protective Factors | 1 | 2020 | 90 | 0.050 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 2019 | 19 | 0.050 |
Why?
| | Leukocyte Disorders | 1 | 2019 | 10 | 0.050 |
Why?
| | Models, Economic | 1 | 2020 | 48 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2020 | 103 | 0.050 |
Why?
| | Markov Chains | 1 | 2020 | 118 | 0.050 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 175 | 0.040 |
Why?
| | Transendothelial and Transepithelial Migration | 1 | 2019 | 27 | 0.040 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2021 | 284 | 0.040 |
Why?
| | Immune System Diseases | 1 | 2019 | 35 | 0.040 |
Why?
| | Tight Junctions | 1 | 2020 | 69 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2013 | 9310 | 0.040 |
Why?
| | Colectomy | 1 | 2020 | 84 | 0.040 |
Why?
| | Feces | 1 | 2022 | 391 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2021 | 2433 | 0.040 |
Why?
| | Neutrophil Activation | 1 | 2019 | 83 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 148 | 0.040 |
Why?
| | Surgical Wound Infection | 1 | 2022 | 251 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 312 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6533 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 410 | 0.040 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2021 | 283 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2020 | 508 | 0.040 |
Why?
| | Adenosine | 1 | 2019 | 211 | 0.040 |
Why?
| | Biological Products | 1 | 2020 | 173 | 0.040 |
Why?
| | Child | 2 | 2022 | 19026 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1405 | 0.040 |
Why?
| | Receptors, CCR2 | 1 | 2017 | 30 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 963 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 538 | 0.040 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2017 | 36 | 0.040 |
Why?
| | Kynurenine | 1 | 2017 | 80 | 0.040 |
Why?
| | Biopsy | 1 | 2020 | 1073 | 0.040 |
Why?
| | Up-Regulation | 1 | 2019 | 861 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 9441 | 0.030 |
Why?
| | Hematopoiesis | 1 | 2017 | 175 | 0.030 |
Why?
| | Signal Transduction | 2 | 2021 | 4676 | 0.030 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 501 | 0.030 |
Why?
| | Incidence | 1 | 2021 | 2413 | 0.030 |
Why?
| | Antibodies | 1 | 2017 | 381 | 0.030 |
Why?
| | Energy Metabolism | 1 | 2020 | 761 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 377 | 0.030 |
Why?
| | Interleukin-10 | 1 | 2017 | 304 | 0.030 |
Why?
| | Wound Healing | 1 | 2017 | 270 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 785 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 949 | 0.030 |
Why?
| | Monocytes | 1 | 2017 | 511 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1588 | 0.030 |
Why?
| | Bacteria | 1 | 2020 | 751 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1771 | 0.030 |
Why?
| | Interferon-gamma | 1 | 2017 | 735 | 0.030 |
Why?
| | Cell Membrane Permeability | 1 | 2013 | 86 | 0.030 |
Why?
| | Nanoparticles | 1 | 2017 | 324 | 0.030 |
Why?
| | Base Sequence | 1 | 2017 | 2140 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1151 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 5072 | 0.030 |
Why?
| | Aged | 1 | 2010 | 19555 | 0.030 |
Why?
| | Adolescent | 1 | 2010 | 18339 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2019 | 4042 | 0.030 |
Why?
| | Pancreatic Neoplasms | 1 | 2018 | 719 | 0.020 |
Why?
| | Granulocytes | 1 | 2011 | 77 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6362 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 142 | 0.020 |
Why?
| | Acute Disease | 1 | 2013 | 933 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1071 | 0.020 |
Why?
| | ROC Curve | 1 | 2011 | 466 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2011 | 186 | 0.020 |
Why?
| | Down-Regulation | 1 | 2011 | 623 | 0.020 |
Why?
| | HeLa Cells | 1 | 2008 | 583 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 1850 | 0.020 |
Why?
| | Cytokines | 1 | 2013 | 1879 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 353 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2011 | 2656 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2652 | 0.010 |
Why?
| | Colorado | 1 | 2011 | 4175 | 0.010 |
Why?
| | Biomarkers | 1 | 2011 | 3564 | 0.010 |
Why?
|
|
Gerich's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|